CSPCY (CSPC Pharmaceutical Group) Total Liabilities : $0 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is CSPC Pharmaceutical Group Total Liabilities?

CSPC Pharmaceutical Group's Total Liabilities for the quarter that ended in Sep. 2024 was $0 Mil.

CSPC Pharmaceutical Group's quarterly Total Liabilities increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($1,574.70 Mil) but then declined from Jun. 2024 ($1,574.70 Mil) to Sep. 2024 ($0.00 Mil).

CSPC Pharmaceutical Group's annual Total Liabilities increased from Dec. 2021 ($1,242.42 Mil) to Dec. 2022 ($1,452.72 Mil) and increased from Dec. 2022 ($1,452.72 Mil) to Dec. 2023 ($1,577.57 Mil).

CSPC Pharmaceutical Group Total Liabilities Historical Data

The historical data trend for CSPC Pharmaceutical Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group Total Liabilities Chart

CSPC Pharmaceutical Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,065.73

1,242.42

1,452.72

1,577.57

1,445.29

CSPC Pharmaceutical Group Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,577.57	-	1,574.70	-	1,445.29

CSPC Pharmaceutical Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CSPC Pharmaceutical Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1426.091	+	(14.994	+	80.507
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	55.977)
	=	1,578

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	6481.915	-	4904.346
	=	1,578

CSPC Pharmaceutical Group's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	55.977)
	=	N/A

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	N/A	-	N/A
	=	N/A

CSPC Pharmaceutical Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CSPC Pharmaceutical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (OTCPK:CSPCY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CHJTF:USA 01093:Hong Kong CVGU:Germany CVG:Germany CVG:Germany

Address

No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035

Website

https://www.cspc.com.hk

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C and antibiotics.

CSPC Pharmaceutical Group Headlines

From GuruFocus

Value Partners Classic Fund Comments on CSPC Pharmaceutical

By Vera Yuan Vera Yuan • 07-29-2014